Aquestive Therapeutics (AQST) Operating Margin (2017 - 2026)

Aquestive Therapeutics' Operating Margin history runs 10 years deep, the most recent figure standing at 29.1% for Q1 2026.

• On a quarterly basis, Operating Margin rose 19297.0% year-over-year to 29.1% in Q1 2026; TTM through Mar 2026 was 838.69%, a 76275.0% decrease from a year earlier, with the FY2025 full-year figure at 7574.73%, down 752128.0% from the prior year.
• Operating Margin declined to 29.1% in Q1 2026 per AQST's latest filing, from 94.27% in the prior quarter.
• Across five years, Operating Margin topped out at 94.27% in Q4 2025 and bottomed at 222.08% in Q1 2025.
• The 5-year median for Operating Margin is 74.31% (2024), against an average of 67.49%.
• Biggest YoY gain for Operating Margin was 20870 bps in 2025; the steepest drop was 14776 bps in 2025.
• Year by year, Operating Margin stood at 100.29% in 2022, then surged by 70 bps to 29.62% in 2023, then sank by 286 bps to 114.43% in 2024, then jumped by 182 bps to 94.27% in 2025, then slumped by 131 bps to 29.1% in 2026.
• Per Business Quant, the three latest AQST Operating Margin figures stand at 29.1% (Q1 2026), 94.27% (Q4 2025), and 89.63% (Q3 2025).